Clinical pattern of psoriasis in patients seen at a tertiary hospital in Nigeria

Ayanlowo, Olusola; Akinkugbe, Ayesha

doi:10.4103/2468-6859.185251

Cited by 11 publications

(18 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was similar to the findings in study by Dogra et al and Ayanlowo et al, but in contrast to Raghunandan et al which showed the peak incidence at third and fourth decade of life. 10,16,17 And Ramani et al which showed peak incidence at the age of 35-55 years. 12 The most common type of psoriasis seen in our study was Psoriasis vulgaris otherwise known as plaque type of psoriasis (82.22%) followed by erythrodermic psoriasis (4.44%) and psoriatic arthritis.…”

Section: Discussionmentioning

confidence: 99%

“…12,15 The most common complaint of the presentation was itching in our study, followed by joint pain which was similar to the findings in Ayanlowo et al where common symptom was itching followed by pain and fever. 10 Itching correlates with severity of psoriasis; leads to impairment in quality of life; the degree of stigmatization and depressive symptoms. 18,19 Neurogenic inflammation with release of neuropeptides from dermal nerve endings; increased dermal vasculature and abnormal functioning of the opioid system among others were thought to be responsible for pruritus in psoriasis.…”

Section: Discussionmentioning

confidence: 99%

“…Knowledge of the environmental triggering factors and their avoidance contributes to the cure or reduction of recurrences/exacerbation. 10 Another shared feature of immune-mediated inflammatory disorder (IMIDs) is the association with other diseases, in particular, cardiovascular diseases. The more commonly associated co-morbidities in psoriasis patient include psoriatic arthritis (PsA) and Crohn's disease, diabetes mellitus, arterial hypertension, rheumatoid arthritis, obesity, ischemic heart disease, depression, and malignancy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A pharmaco-epidemiological study of psoriasis

Gupta

Acharya²,

Shanmukha³

et al. 2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Psoriasis is a chronic relapsing disease necessitates long-term therapy. The disease severity, comorbidities, and access to health care determine the choice of therapy for psoriasis. The main aim of the treatment of psoriasis is to induce prolonged remission and suppress the disease as there is no cure. It is only palliative and symptomatic treatment, and the choice of treatment modality is according to the type of presentation. The various modalities of treatment available include topical therapies, systemic therapies, phototherapy, and biologics. The difference includes among clinical varieties in their presenting features, severity, natural course, and response to the treatment are responsible for variation in choice of therapy.Methods: In this descriptive study, data collected from patients diagnosed with psoriasis who were admitted in a K.S. Hegde Charitable hospital from January 2017 to January 2019 were analysed for demographic features, disease pattern and drug use pattern in patients.Results: Psoriasis vulgaris/plaque type of psoriasis was commonly observed type of psoriasis in our patients with fourth and fifth decade patients getting more affected. Diabetes was the most commonly associated comorbid disorder. The patients were treated both with systemic and topical modalities of treatment, antihistaminic and methotrexate were most commonly most commonly used systemic drug and moisturizers and glucocorticoids were used topical drugs.Conclusions: Psoriasis needs a multimodality treatment with careful monitoring for the comorbid disorder. Treatment choice is individualised depending on the severity and body parts affected.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

A pharmaco-epidemiological study of psoriasis

Gupta

Acharya²,

Shanmukha³

et al. 2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…The pathogenesis is not well understood but is believed to be multifactorial with a pivotal involvement of the immune system, specifically T-cells, after an inciting event in a genetically predisposed individual [ 1 - 5 ]. The global burden of psoriasis is between 1.5%-5.0% but reaches up to 11% in developed countries [ 1 , 2 , 6 ]. Data about incidence, prevalence, and the clinical profile of patients with psoriasis in the middle east, particularly Saudi Arabia, are lacking.…”

Section: Introductionmentioning

confidence: 99%

“…Studies on the patterns of comorbidities seen with psoriasis have been explored in numerous countries on various races and ethnicities, but these patterns have only been slightly investigated in the Saudi population [ 2 , 10 , 12 , 13 ]. Due to the distinct nature of psoriasis types, classifications, and clinical presentations that separates it from other dermatological conditions, it is essential to investigate patterns of different comorbidities and diseases with psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Patterns of Comorbidities in Psoriasis Patients: A Cross-Sectional Study

Alajmi

Alamoudi

Alabbasi

et al. 2021

Cureus

View full text Add to dashboard Cite

Background: Psoriasis is a chronic, inflammatory, and immune-mediated dermatological disease of unknown etiology with predominant involvement of the skin, nails, and joints. This study aimed to assess comorbidities patterns in psoriasis patients. Methods: This is a cross-sectional study conducted at King Abdulaziz Medical City (KAMC) in Jeddah, Saudi Arabia. Data were collected through a retrospective chart review of the electronic medical record system (Bestcare, Ezcaretech, Seoul, Korea) and by utilizing a structured data collection sheet. Results: A total of 128 confirmed psoriasis cases were included with a mean age of 44.2 ± 17.3. The sample had 45.7% females and 54.3% males. Nearly half the patients (46.1%) had no comorbidities, followed by those who had at least one comorbidity (24.2%) and those who had two or more comorbidities (29.7%). Most patients were classified as plaque psoriasis (57.0%), followed by those who had psoriatic arthritis (13.3%). There was no statistical significance between gender, body mass index (BMI), and smoking with the number of comorbidities (P= 0.422, P=0.361, P=0.772); 41.2% of psoriatic arthritis patients and all erythrodermic arthritis patients had two or more comorbidities, which is statistically significant at p -value <0.018. Conclusion: This study demonstrated the prevalence of different comorbidities associated with psoriasis patients; 41.2% of psoriatic arthritis patients and all erythrodermic arthritis patients had two or more comorbidities, which was statistically significant. This necessitates closer monitoring of different comorbidities a psoriasis patient might present with. Especially those who are diagnosed with psoriatic arthritis and erythrodermic arthritis.

show abstract